Bio-Techne shares rose 5.0% this afternoon to a price of $80.36. The stock is still trading within range of its average target price of $83.32, and over the last 52 weeks, it has recorded a 9.4% performance. Analysts have given the Large-Cap Biotechnology stock target prices ranging from $65.0 to $95.0 dollars per share, with an average rating of buy.
Bio-Techne's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.4%. The stock's short ratio is 3.31. The company's insiders own 1.02% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 100.2%. In conclusion, we believe there is positive market sentiment regarding Bio-Techne.
Institutions Invested in Bio-Techne
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Vanguard Group Inc | 11% | 18,181,854 | $1,461,093,798 |
| 2024-06-30 | Blackrock Inc. | 9% | 14,987,870 | $1,204,425,242 |
| 2024-06-30 | Price (T.Rowe) Associates Inc | 5% | 8,525,772 | $685,131,043 |
| 2024-06-30 | State Street Corporation | 4% | 6,300,860 | $506,337,113 |
| 2024-06-30 | BAMCO Inc. | 3% | 4,776,592 | $383,846,936 |
| 2024-06-30 | Morgan Stanley | 3% | 4,410,696 | $354,443,533 |
| 2024-06-30 | Ameriprise Financial, Inc. | 3% | 4,102,418 | $329,670,312 |
| 2024-06-30 | Geode Capital Management, LLC | 2% | 3,906,378 | $313,916,538 |
| 2024-06-30 | Neuberger Berman Group, LLC | 2% | 3,535,895 | $284,144,524 |
| 2024-06-30 | Df Dent & Co Inc | 2% | 3,374,366 | $271,164,053 |
